Zhen Zhao

Dr. Zhen Zhao

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
Zhen ZhaoZhen Zhao
Zhen Zhao
YLYuanke Li
Yuanke Li
HLHao Liu
Hao Liu
AJAkshay Jain
Akshay Jain
PPPratikkumar Vinodchandra Patel
Pratikkumar Vinodchandra Patel
Kun ChengKun Cheng
Kun Cheng
IKBKE is an oncogene in triple-negative breast cancer (TNBC), and we demonstrate that IKBKE small interfering RNA (siRNA) inhibits the proliferation, migration, and invasion of TNBC cells. Despite the recent success of siRNA therapeutics targeting to the liver, there still remains a great challenge to deliver siRNAs to solid tumors. Here, we report a hybrid nanocomplex to co-deliver the IKBKE siRNA and cabazitaxel to TNBC to achieve an optimal antitumor effect. The nanocomplex is modified with hyaluronic acid to target CD44 on TNBC cells. The nanocomplex shows higher cellular uptake and better tumor penetration of the encapsulated cargos. The nanocomplex also exhibits high tumor accumulation and antitumor activity in an orthotopic TNBC mouse model. Encapsulation of cabazitaxel in the nanocomplex enhances the activity of the IKBKE siRNA. The hybrid nanocomplex provides a novel and versatile platform for combination therapies using siRNAs and chemotherapy.

15 January 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
YLYuanke Li
Yuanke Li
LYLiu r Ying
Liu r Ying
Zhen ZhaoZhen Zhao
Zhen Zhao
Brain diseases pose significant treatment challenges due to the restrictive nature of the blood–brain barrier (BBB). Recent advances in targeting macromolecules offer promising avenues for overcoming these obstacles through receptor-mediated transcytosis (RMT). We summarize the current progress in targeting brain drug delivery with macromolecules for brain diseases. This exploration details the transport mechanisms across the BBB, focusing on RMT and its use of natural ligands for drug delivery. Furthermore, the review examines macromolecular ligands such as antibodies, peptides, and aptamers that leverage RMT for effective BBB traversal. Advancements in macromolecules-based delivery systems for brain diseases are summarized, emphasizing their therapeutic potential and limitations. Finally, emerging RMT strategies, including viral vectors, exosomes, and boron neutron capture therapy, are discussed for their precision in brain-targeted treatments. This comprehensive overview underscores the potential of RMT-based approaches to revolutionize brain disease therapy.

21 February 2024 in Journal of Agricultural and Food Chemistry
Verified
Journal Article
Closed access
BMBiao Ma
Biao Ma
SSSai Shi
Sai Shi
WGWei Guo
Wei Guo
HZHailin Zhang
Hailin Zhang
Zhen ZhaoZhen Zhao
Zhen Zhao
HAHailong An
Hailong An

2 December 2023 in European Journal of Pharmacology
Verified
Journal Article
Closed access
BMBiao Ma
Biao Ma
SSSai Shi
Sai Shi
SRShuxi Ren
Shuxi Ren
CQChang Qu
Chang Qu
Zhen ZhaoZhen Zhao
Zhen Zhao
HAHailong An
Hailong An